HCA
ALNY icon

Harbor Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Harbor Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$564K Buy
+1,704
New +$580K 0.05% 458
2025
Q1 		– Sell
-2,650
Closed -$624K – 1405
2024
Q4 		$624K Buy
2,650
+63
+2% +$16.6K 0.03% 522
2024
Q3 		$712K Buy
2,587
+9
+0.3% +$2.34K 0.03% 514
2024
Q2 		$626K Buy
2,578
+10
+0.4% +$1.58K 0.05% 478
2024
Q1 		$384K Sell
2,568
-370
-13% -$61.7K 0.05% 466
2023
Q4 		$562K Buy
2,938
+51
+2% +$8.69K 0.11% 227
2023
Q3 		$511K Buy
2,887
+163
+6% +$31.1K 0.11% 225
2023
Q2 		$517K Sell
2,724
-14
-0.5% -$2.78K 0.1% 240
2023
Q1 		$548K Buy
2,738
+2,363
+630% +$497K 0.16% 133
2022
Q4 		$89.1K Sell
375
-22
-6% -$4.69K 0.09% 91
2022
Q3 		$79K Sell
397
-811
-67% -$155K 0.07% 107
2022
Q2 		$176K Buy
1,208
+108
+10% +$15.3K 0.13% 85
2022
Q1 		$180K Buy
+1,100
New +$168K 0.08% 98

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbor Capital Advisors's ALNY Position: Q1 2026 in Review

Harbor Capital Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 1,704 shares worth $564K. The stake represents 0.05% of the portfolio and ranks #458 among its holdings. This is a return to the name: Harbor Capital Advisors previously reported a position in ALNY as recently as Q4 2024.

Harbor Capital Advisors first reported a position in ALNY in Q1 2022 and has held it in 13 quarters since. The position peaked at $712K in Q3 2024. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Harbor Capital Advisors held 1,704 shares of Alnylam Pharmaceuticals worth $564K as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Harbor Capital Advisors position in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.05% of Harbor Capital Advisors's portfolio in Q1 2026, its #458 holding.
  • Harbor Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • Harbor Capital Advisors's Alnylam Pharmaceuticals position peaked at $712K in Q3 2024.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.